Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
Seungyeon JungEmma ArmstrongAlexander Z WeiFei YeAaron LeeMatteo S CarlinoRyan J SullivanRichard D CarvajalAlexander N ShoushtariDouglas B JohnsonPublished in: British journal of cancer (2022)
This multicenter study highlights KIT-alterations sensitive to imatinib and augments evidence for imatinib in subsets of KIT-altered melanoma.
Keyphrases